OneMedNet

OneMedNet

OneMedNet was founded in 2009 to address a stubborn bottleneck in drug development: the difficulty of finding high-quality, de-identified medical imaging paired with longitudinal clinical outcomes. The company partners with healthcare providers to curate, de-identify, and organize imaging studies — primarily in oncology, cardiology, and neurology — into searchable registries that pharmaceutical firms and AI developers license for R&D. Rather than scraping administrative claims, OneMedNet's model relies on direct provider relationships, which yields imaging cohorts that are more precisely characterized and more useful for training regulatory-grade algorithms. The firm's commercial engine is its iRWD platform, which allows life-science customers to query complex clinical parameters and receive matched, de-identified imaging data sets on demand. Use cases span clinical-trial feasibility assessments, external control arms, and AI model development. OneMedNet's revenue comes from data-licensing agreements, typically structured as multi-year subscriptions with top-20 pharma companies and leading imaging-AI startups. In 2023 the company went public via a business combination with Data Knights Acquisition Corp., listing on the Nasdaq under the symbol ONMD, which provided capital to expand its provider network beyond its initial Midwestern base. Since the public listing, the company has announced a partnership with an oncology-focused AI firm to build a federated data network across multiple European sites (per the firm, late 2023), signaling an international expansion of its curation model. As a micro-cap public company, OneMedNet operates with a lean structure. CEO Aaron Green, who has led the company since its early-stage days, manages a team that combines clinical informatics specialists with business-development professionals targeting the top 30 global pharmaceutical firms. The company does not disclose total dataset size or exact partner counts, but regulatory filings reference a growing library of oncology and cardiovascular imaging studies sourced from US health systems. The firm has not disclosed any related philanthropic structures or adjacent investment vehicles. OneMedNet's structural differentiator is its position as one of the few pure-play, publicly traded real-world imaging data companies — a sub-category that sits between large-scale claims-data aggregators and bespoke clinical-research organizations. Its public-company status creates unusual transparency for a data-curation business, subjecting its deal flow, customer concentration, and provider-partnership churn to quarterly disclosure. For an industry that typically operates behind NDAs and private valuations, that transparency is rare.